Dyne Therapeutics, Inc. $DYN Shares Bought by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Dyne Therapeutics stake by 48.1% in the third quarter, adding 80,321 shares to hold 247,403 shares valued at about $4.0 million.
• Institutional investors own 96.68% of DYN, while company insiders sold about 2.6 million shares worth $65.4 million over the last quarter. Some sales were made under pre-arranged plans or to cover tax obligations.
• Dyne reported a third-quarter loss of $1.06 per share, wider than analysts’ expected $0.91 loss. The company also has a near-term regulatory catalyst: the FDA’s priority review of its DMD candidate has a target action date of January 21, 2027.

Alps Advisors Inc. grew its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 48.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 247,403 shares of the company's stock after purchasing an additional 80,321 shares during the quarter. Alps Advisors Inc. owned approximately 0.13% of Dyne Therapeutics worth $3,986,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Dyne Therapeutics by 63.2% during the third quarter. GAMMA Investing LLC now owns 1,882 shares of the company's stock valued at $30,000 after acquiring an additional 729 shares during the period. Allworth Financial LP bought a new stake in Dyne Therapeutics during the 2nd quarter valued at approximately $62,000. Sterling Capital Management LLC grew its holdings in Dyne Therapeutics by 89.8% in the 3rd quarter. Sterling Capital Management LLC now owns 3,720 shares of the company's stock valued at $60,000 after buying an additional 1,760 shares during the last quarter. Nykredit A S acquired a new stake in Dyne Therapeutics in the 2nd quarter valued at approximately $113,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in Dyne Therapeutics in the 2nd quarter valued at approximately $114,000. 96.68% of the stock is owned by institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox sold 5,658 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the transaction, the chief executive officer owned 357,507 shares in the company, valued at approximately $6,749,732.16. This represents a 1.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason Rhodes sold 2,160,516 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company's stock, valued at $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,598,706 shares of company stock worth $65,432,671. Corporate insiders own 9.46% of the company's stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $18.07 on Monday. Dyne Therapeutics, Inc. has a 12 month low of $14.00 and a 12 month high of $27.31. The company has a market capitalization of $3.39 billion, a P/E ratio of -4.98 and a beta of 1.22. The stock has a 50 day moving average of $17.70 and a two-hundred day moving average of $19.33. The company has a current ratio of 12.99, a quick ratio of 12.99 and a debt-to-equity ratio of 0.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.15). During the same quarter last year, the business posted ($0.76) earnings per share. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.69 EPS for the current year.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: The FDA is conducting a priority review of Dyne’s biologics license application for z-rostudirsen, its exon 51 Duchenne muscular dystrophy (DMD) candidate. The FDA’s target action date is January 21, 2027, providing a defined near-term regulatory catalyst. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Management said its cash runway extends into the second quarter of 2028, providing funding visibility for ongoing development. The company also reported progress in its DMD and DM1 programs ahead of planned 2027 milestones. Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
• Neutral Sentiment: A valuation commentary raised the possibility that DYN is undervalued, citing its pipeline and the FDA priority review, but this is an opinion rather than a new company development. Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
• Negative Sentiment: Third-quarter EPS was a loss of $1.06, wider than analysts’ expected $0.91 loss and the $0.76 loss a year earlier. Reports attributed the increased loss to higher research and development spending, highlighting rising development costs. Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

Analyst Ratings Changes

DYN has been the subject of a number of research analyst reports. HC Wainwright cut their price target on Dyne Therapeutics from $50.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, September 30th. Wall Street Zen downgraded shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Oppenheimer lowered shares of Dyne Therapeutics from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $40.00 to $15.00 in a research report on Wednesday, October 28th. Stifel Nicolaus set a $37.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Finally, Chardan Capital reiterated a "buy" rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.29.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company's programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.